Sign in Register

Drug class

Smoking Deterrents - Nicotinic

"Smoking Deterrents - Nicotinic" is a formulary and compendial classification rather than a formal standalone FDA pharmacologic class, encompassing therapeutic nicotine-replacement therapies such as transdermal patches, polacrilex gums, lozenges, inhalers, and nasal sprays. Read more about Smoking Deterrents - Nicotinic

115 drugs in this class 60 manufacturers

Related classes & indications

Antipsychotics, AtypicalCNS, pain & psychiatry · 296 prescription drugs Antidepressant Serotonin-Norepinephrine Reuptake Inh.(SNRIs)CNS, pain & psychiatry · 127 prescription drugs Smoking CessationTop indication · 45 prescription drugs

Showing 82–90 of 115 drugs

Sort

NICOTINE LOZENGE (nicotine polacrilex)

SMOKING DETERRENTS - NICOTINIC OR BUPROPION (NDRI)-TYPE · SMOKING CESSATION

RISING PHARM

VARENICLINE TARTRATE

SMOKING DETERRENTS - NICOTINIC OR BUPROPION (NDRI)-TYPE · SMOKING CESSATION

ASCEND LABORATO

NICOTINE PATCH (nicotine)

SMOKING DETERRENTS - NICOTINIC OR BUPROPION (NDRI)-TYPE · SMOKING CESSATION

BLUEPOINT LABOR

VARENICLINE TARTRATE

SMOKING DETERRENTS - NICOTINIC OR BUPROPION (NDRI)-TYPE · SMOKING CESSATION

LUPIN PHARMACEU

NICOTINE GUM (nicotine polacrilex)

SMOKING DETERRENTS - NICOTINIC OR BUPROPION (NDRI)-TYPE · SMOKING CESSATION

SAM'S WEST INC

VARENICLINE TARTRATE

SMOKING DETERRENTS - NICOTINIC OR BUPROPION (NDRI)-TYPE · SMOKING CESSATION

GLENMARK PHARMA

VARENICLINE TARTRATE

SMOKING DETERRENTS - NICOTINIC OR BUPROPION (NDRI)-TYPE · SMOKING CESSATION

LEADING PHARMA

VARENICLINE TARTRATE

SMOKING DETERRENTS - NICOTINIC OR BUPROPION (NDRI)-TYPE · SMOKING CESSATION

ZYDUS PHARMACEU

VARENICLINE TARTRATE

SMOKING DETERRENTS - NICOTINIC OR BUPROPION (NDRI)-TYPE · SMOKING CESSATION

FLORIDA PHARMAC

Filter & compare in the drug finder → Opens the drug finder with Smoking Deterrents - Nicotinic preselected. Add indication or manufacturer filters there.

About Smoking Deterrents - Nicotinic.

"Smoking Deterrents - Nicotinic" is a formulary and compendial classification rather than a formal standalone FDA pharmacologic class, encompassing therapeutic nicotine-replacement therapies such as transdermal patches, polacrilex gums, lozenges, inhalers, and nasal sprays.

These agents function as nicotinic acetylcholine receptor agonists, providing controlled systemic delivery of nicotine to alleviate withdrawal symptoms and suppress cravings without the harmful toxins and carcinogens associated with combusted tobacco.

Their primary clinical indication is tobacco use disorder, serving as an aid to smoking cessation and long-term relapse prevention, frequently alongside behavioral support.

fda.gov
"Smoking Deterrents - Nicotinic" is a formulary and compendial classification rather than a formal standalone FDA pharmacologic class, encompassing therapeutic nicotine-replacement therapies such as transdermal patches, polacrilex gums, lozenges, inhalers, and nasal sprays Their primary clinical indication is tobacco use disorder, serving as an aid to smoking cessation and long-term relapse prevention, frequently alongside behavioral support
fda.gov
"Smoking Deterrents - Nicotinic" is a formulary and compendial classification rather than a formal standalone FDA pharmacologic class, encompassing therapeutic nicotine-replacement therapies such as transdermal patches, polacrilex gums, lozenges, inhalers, and nasal sprays These agents function as nicotinic acetylcholine receptor agonists, providing controlled systemic delivery of nicotine to alleviate withdrawal symptoms and suppress cravings without the harmful toxins and carcinogens associate...
ventegra.org
"Smoking Deterrents - Nicotinic" is a formulary and compendial classification rather than a formal standalone FDA pharmacologic class, encompassing therapeutic nicotine-replacement therapies such as transdermal patches, polacrilex gums, lozenges, inhalers, and nasal sprays
cdc.gov
"Smoking Deterrents - Nicotinic" is a formulary and compendial classification rather than a formal standalone FDA pharmacologic class, encompassing therapeutic nicotine-replacement therapies such as transdermal patches, polacrilex gums, lozenges, inhalers, and nasal sprays
fda.gov
These agents function as nicotinic acetylcholine receptor agonists, providing controlled systemic delivery of nicotine to alleviate withdrawal symptoms and suppress cravings without the harmful toxins and carcinogens associated with combusted tobacco Their primary clinical indication is tobacco use disorder, serving as an aid to smoking cessation and long-term relapse prevention, frequently alongside behavioral support
smokefree.gov
These agents function as nicotinic acetylcholine receptor agonists, providing controlled systemic delivery of nicotine to alleviate withdrawal symptoms and suppress cravings without the harmful toxins and carcinogens associated with combusted tobacco